Author:
Lee Jung Yeon,Park Sung-Soo,Jeon Young-Woo,Shin Seung-Hwan,Yahng Seung-Ah,Min Chang-Ki,
Funder
Ministry of Health and Welfare
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference46 articles.
1. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T et al (2016) Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood, the Journal of the American Society of Hematology 128(9):1174–1180
2. Bensinger WI (2004) The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma. J Natl Compr Canc Netw 2(4):371–378
3. Bringhen S, D'Agostino M, Giuliani N, Attucci I, Zambello R, Ronconi S, et al. Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial. Blood. 2022;140(Supplement 1):1814–6.
4. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27–38
5. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G et al (2021) Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(†). Ann Oncol 32(3):309–322
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献